Cost-effectiveness analysis of first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations

Research output: Contribution to journal › Article › Academic › peer-review

20 Citations (Scopus)

2 Downloads (Pure)

Original language	English
Pages (from-to)	153-164
Number of pages	12
Journal	The European Journal Of Health Economics
Volume	21
DOIs	https://doi.org/10.1007/s10198-019-01117-3
Publication status	Published - 2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

@article{007050a840504283b905c5de6a67df0f,

title = "Cost-effectiveness analysis of first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations",

author = "Marscha Holleman and Maiwenn Al and Remziye Zaim and HJM Groen and {Uyl - de Groot}, Carin",

year = "2019",

doi = "10.1007/s10198-019-01117-3",

language = "English",

volume = "21",

pages = "153--164",

journal = "European Journal of Health Economics",

issn = "1439-3972",

publisher = "Springer-Verlag",

}

TY - JOUR

T1 - Cost-effectiveness analysis of first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations

AU - Holleman, Marscha

AU - Al, Maiwenn

AU - Zaim, Remziye

AU - Groen, HJM

AU - Uyl - de Groot, Carin

PY - 2019

Y1 - 2019

U2 - 10.1007/s10198-019-01117-3

DO - 10.1007/s10198-019-01117-3

M3 - Article

VL - 21

SP - 153

EP - 164

JO - European Journal of Health Economics

JF - European Journal of Health Economics

SN - 1439-3972

ER -